Mayukh Sukhatme Sells 185,946 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Mayukh Sukhatme sold 185,946 shares of the company’s stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total transaction of $2,231,352.00. Following the transaction, the executive now owns 18,836,547 shares of the company’s stock, valued at $226,038,564. This trade represents a 0.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Mayukh Sukhatme also recently made the following trade(s):

• On Thursday, December 26th, Mayukh Sukhatme sold 689,495 shares of Roivant Sciences stock. The stock was sold at an average price of $12.01, for a total value of $8,280,834.95.
• On Wednesday, December 18th, Mayukh Sukhatme sold 412,584 shares of Roivant Sciences stock. The shares were sold at an average price of $12.05, for a total value of $4,971,637.20.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV remained flat at $12.00 during trading on Thursday. 3,300,963 shares of the stock were exchanged, compared to its average volume of 5,778,284. Roivant Sciences Ltd. has a 12 month low of $9.69 and a 12 month high of $13.06. The business’s 50 day moving average is $11.91 and its two-hundred day moving average is $11.51. The stock has a market capitalization of $8.74 billion, a PE ratio of 2.12 and a beta of 1.25.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Bank of America raised their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a report on Wednesday, September 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Finally, HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.93.

Institutional Trading of Roivant Sciences

A number of institutional investors have recently bought and sold shares of ROIV. nVerses Capital LLC acquired a new position in shares of Roivant Sciences in the 2nd quarter valued at about $34,000. Gladius Capital Management LP bought a new stake in Roivant Sciences in the third quarter worth approximately $35,000. Point72 Hong Kong Ltd acquired a new position in Roivant Sciences in the second quarter valued at approximately $36,000. US Bancorp DE boosted its holdings in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares in the last quarter. Finally, Quarry LP acquired a new stake in shares of Roivant Sciences during the 2nd quarter worth approximately $53,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.